As rats have been nibbling at the edges of society, UA researchers were developing a non-reproductive rodent model for studying menopause. That work yielded a humane, non-lethal rodent infertility formulation, now being commercialized by startup SenesTech.

In the lab of Louise Hecker, PhD, researchers have invented the first highly selective Nox4 small molecule inhibitors for the treatment of fibrotic disorders. The UA has licensed the technology to startup Fibronox to bring the invention to the public.

Six teams went head-to-head during a shark tank-style competition hosted by the College of Medicine – Tucson. For their work to reduce asthma attacks, Monica Kraft, MD, and Julie Ledford, PhD, were named the competition winners.

Last year, the drivers behind startup SinfoniaRx announced the launch of UAVenture Capital to support commercialization at the UA. Now, they are announcing a second fund targeting $100 million to further the advance of UA innovations.

Through TLA, the University of Arizona is partnering with Kerafast to license reagents that offer the opportunity for the development of a rapid, highly sensitive diagnostic test for Cryptosporidiosis, the leading cause of waterborne diseases among people in the U.S.

Researchers at the University of Arizona have discovered a protein that prevents mosquitoes from hatching, opening the possibility of developing new drugs that could act as birth control for mosquito populations.